Combination therapy of gemcitabine or oral S-1 with the anti-VEGF monoclonal antibody bevacizumab for pancreatic neuroendocrine carcinoma.
about
Blocking SDF-1α/CXCR4 downregulates PDGF-B and inhibits bone marrow-derived pericyte differentiation and tumor vascular expansion in Ewing tumors.Trifluridine/tipiracil increases survival rates in peritoneal dissemination mouse models of human colorectal and gastric cancer.Sequential treatment in disseminated well- and intermediate-differentiated pancreatic neuroendocrine tumors: Common sense or low rationale?
P2860
Combination therapy of gemcitabine or oral S-1 with the anti-VEGF monoclonal antibody bevacizumab for pancreatic neuroendocrine carcinoma.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Combination therapy of gemcita ...... atic neuroendocrine carcinoma.
@ast
Combination therapy of gemcita ...... atic neuroendocrine carcinoma.
@en
type
label
Combination therapy of gemcita ...... atic neuroendocrine carcinoma.
@ast
Combination therapy of gemcita ...... atic neuroendocrine carcinoma.
@en
prefLabel
Combination therapy of gemcita ...... atic neuroendocrine carcinoma.
@ast
Combination therapy of gemcita ...... atic neuroendocrine carcinoma.
@en
P2093
P2860
P356
P1476
Combination therapy of gemcita ...... atic neuroendocrine carcinoma.
@en
P2093
Akihiko Tsuchida
Kazuhiko Kasuya
Minako Suzuki
Satoru Suzuki
Takaaki Matsudo
Takao Itoi
Tatsuya Aoki
Yoshiaki Suzuki
Yuichi Nagakawa
P2860
P304
P356
10.3892/ETM.2012.456
P577
2012-01-18T00:00:00Z